Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Laekna Acquires Global Rights to Novartis Clinical-Stage PD-L1

publication date: Mar 24, 2020

Laekna Therapeutics Shanghai acquired global rights to Novartis' anti-PD-L1 antibody (FAZ053), the third deal between Laekna and Novartis. In a Phase I trial, FAZ053 demonstrated a tolerable safety profile and clinical efficacy in diverse solid tumors. Laekna plans new trials that combine the PD-L1 with chemotherapies. Previously, Laekna in-licensed global rights from Novartis to a small-molecule tumor treatment, and two oral AKT pan inhibitors. Laekna also conducts R&D on its own in-house projects. In 2019, the company completed a $27.5 million B financing, led by GP Healthcare.

Stock Symbol: (NYSE: NVS)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.